Statin treatment and mortality in bacterial infections - a systematic review and meta-analysis

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Björkhem Bergman, Linda ^a   Bergman, Peter ^a   Andersson, Jan ^a   Lindh, Jonatan D ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BACTEREMIA; BACTERIAL INFECTION; CAUSE OF DEATH; CITATION ANALYSIS; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; INFECTION RISK; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PNEUMONIA; POSTOPERATIVE INFECTION; PROGNOSIS; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BACTERIAL INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; SENSITIVITY AND SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 77956542993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010702     Document Type: Review

References (58)

1. Kopterides P, Falagas ME (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15: 325-334.
2. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122-2132.
3. Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330.
4. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987.
5. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama 286: 64-70.
6. Broady R, Levings MK (2008) Graft-versus-host disease: suppression by statins. Nat Med 14: 1155-1156.
7. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627.
8. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, et al. (2009) HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. pp CD005019.
9. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, et al. (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169: 1658-1667.
10. Stanley TD (2008) Meta-Regression Method for Detecting and Estimating Empirical Effects in the Presence of Publication Selection. Oxford Bulletin of Economics and Statistic 70: 103-127.
11. Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15: 291-303.
12. Frost FJ, Petersen H, Tollestrup K, Skipper B (2007) Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131: 1006-1012.
13. Almog Y, Novack V, Eisinger M, Porath A, Novack L, et al. (2007) The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 35: 372-378.
14. Coleman CI, Lucek DM, Hammond J, White CM (2007) Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 23: 1783-1790.
15. Daneman N, Thiruchelvam D, Redelmeier DA (2009) Statin use and the risk of surgical site infections in elderly patients undergoing elective surgery. Arch Surg 144: 938-945.
16. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM (2009) Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29: 621-630.
17. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, et al. (2009) Statin use and risk of community acquired pneumonia in older people: population based case-control study. Bmj 338: b2137.
18. Fernandez R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32: 160-164.
19. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect: 1-8.
20. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, et al. (2007) Statin use and sepsis events [corrected] in patients with chronic kidney disease. Jama 297: 1455-1464.
21. Hackam DG, Mamdani M, Li P, Redelmeier DA (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367: 413-418.
22. Hauer-Jensen M, Fort C, Mehta JL, Fink LM (2006) Influence of statins on postoperative wound complications after inguinal or ventral herniorrhaphy. Hernia 10: 48-52.
23. Ishida W, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, et al. (2007) Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 212: 265-273.
24. Kwong JC, Li P, Redelmeier DA (2009) Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 4: e8087.
25. Mohamed R, McAlister FA, Pretorius V, Kapoor AS, Majumdar SR, et al. (2009) Preoperative statin use and infection after cardiac surgery: a cohort study. Clin Infect Dis 48: e66-72.
26. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, et al. (2008) Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 15: 82-90.
27. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, et al. (2009) Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 18: 269-275.
28. Neal MD, Cushieri J, Rosengart MR, Alarcon LH, Moore EE, et al. (2009) Preinjury statin use is associated with a higher risk of multiple organ failure after injury: a propensity score adjusted analysis. J Trauma 67: 476-482; discussion 482-474.
29. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR (2007) Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27: 325-332.
30. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67: 99-109.
31. Subramaniam K, Koch CG, Bashour A, O'Connor M, Xu M, et al. (2008) Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anesth 20: 4-11.
32. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, et al. (2007) Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 38: 1545-1550.
33. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, et al. (2006) Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61: 957-961.
34. Almog Y, Shefer A, Novack V, Maimon N, Barski L, et al. (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885.
35. Chalmers JD, Singanayagam A, Murray MP, Hill AT (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007 e1001.
36. de Saint Martin L, Tande D, Goetghebeur D, Pan-Lamande M, Segalen Y, et al. (2009) Statin use does not affect the outcome of acute infection: a prospective cohort study. Presse Med.
37. Donnino MW, Cocchi MN, Howell M, Clardy P, Talmor D, et al. (2009) Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 16: 230-234.
38. Hsu J, Andes DR, Knasinski V, Pirsch J, Safdar N (2009) Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients. Eur J Clin Microbiol Infect Dis.
39. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32: 75-79.
40. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33: 1352-1357.
41. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. Bmj 333: 999.
42. Martin CP, Talbert RL, Burgess DS, Peters JI (2007) Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27: 20-26.
43. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, et al. (2008) Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 31: 611-617.
44. Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2005) The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 6: 82.
45. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, et al. (2007) Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 27: 1619-1626.
46. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, et al. (2009) The impact of statins, ace inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 18: 697-703.
47. Schmidt H, Hennen R, Keller A, Russ M, Muller-Werdan U, et al. (2006) Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 32: 1248-1251.
48. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, et al. (2006) Statin use and mortality within 180 days after bacteremia: a populationbased cohort study. Crit Care Med 34: 1080-1086.
49. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, et al. (2008) Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 168: 2081-2087.
50. Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, et al. (2007) Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 25: 494-501.
51. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
52. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Bmj 326: 1167-1170.
53. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, et al. (2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119: 2051-2057.
54. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203: 401-412.
55. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S (2008) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+lymphocytes. J Immunol 180: 6988-6996.
56. Senthamil Selvan P, Pal TK (2009) Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. J Pharm Biomed Anal 49: 780-785.
57. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH (2001) Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111: 185-191.
58. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, et al. (2009) Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 26: 958-964.